Aleniglipron
GSBR-1290
Gasherbrum Bio, Inc · Phase 2 · Completed · Enrollment 58
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Arm 1: Participants will receive aleniglipron administered orally | n/r | n/r | n/r | n/r | n/r |
| Arm 2: Participants will receive a placebo administered orally | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.